| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $18,922,198 | 4 | 100 |
| Purdue David Ryan | SVP, Controller | 0 | $0 | 1 | $1.22M | $-1.22M |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 0 | $0 | 1 | $8.18M | $-8.18M |
| Siatis Perry C | EVP, GC AND SECRETARY | 0 | $0 | 2 | $9.52M | $-9.52M |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For …
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $18.92M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $0 and sold $79.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
| 2026-08-14 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 32,710 0.0019% | $250.00 | $8.18M | +6.24% | |
| 2026-03-04 | Sale | Purdue David Ryan | SVP, Controller | 5,230 0.0003% | $233.56 | $1.22M | +5.85% | |
| 2026-03-02 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 18,668 0.0011% | $234.39 | $4.38M | +6.65% | |
| 2026-02-25 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 22,381 0.0013% | $230.00 | $5.15M | +9.46% | |
| 2025-08-12 | Sale | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 42,370 0.0024% | $198.42 | $8.41M | +13.76% | |
| 2025-08-05 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 13,295.17 0.0008% | $198.51 | $2.64M | +13.59% | |
| 2025-03-31 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,832 0.0033% | $210.08 | $12.36M | +5.73% | |
| 2025-03-14 | Sale | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 17,644 0.001% | $212.34 | $3.75M | +4.21% | |
| 2025-03-03 | Sale | GONZALEZ RICHARD A | director | 6,168 0.0003% | $210.53 | $1.3M | +1.41% | |
| 2025-03-03 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 21,250 0.0012% | $210.45 | $4.47M | +1.41% | |
| 2025-03-03 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 18,008 0.001% | $210.00 | $3.78M | +1.41% | |
| 2025-02-28 | Sale | GONZALEZ RICHARD A | director | 92,460 0.0052% | $205.11 | $18.96M | +2.54% | |
| 2025-02-28 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,892 0.0006% | $206.30 | $2.04M | +2.54% | |
| 2025-02-26 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 29,917 0.0017% | $202.90 | $6.07M | +5.51% | |
| 2025-02-26 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 18,944 0.0011% | $203.41 | $3.85M | +5.51% | |
| 2025-02-20 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 5,778 0.0003% | $197.90 | $1.14M | +6.31% | |
| 2024-12-16 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 1,800 0.0001% | $172.24 | $310,032 | +17.94% | |
| 2024-08-05 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 66,500 0.0038% | $186.52 | $12.4M | +4.80% | |
| 2024-07-17 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 282,845 0.016% | $175.00 | $49.5M | +9.60% | |
| 2024-03-20 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | +3.60% |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 74430 0.0042% | $21.29M | 1 | 4 | +35.37% |
| Schumacher Laura J | Vice Chairman | 213003 0.0121% | $60.92M | 1 | 14 | +27.77% |
| CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $48.49M | 1 | 7 | +28.05% |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 53234 0.003% | $15.22M | 1 | 9 | +37.99% |
| Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $11.9M | 1 | 6 | +30.66% |
| TILTON GLENN F | director | 39735 0.0022% | $11.36M | 1 | 0 | <0.0001% |
| AUSTIN ROXANNE S | director | 34483 0.002% | $9.86M | 4 | 3 | +31.03% |
| Durkin Brian L | VP, Controller | 19094 0.0011% | $5.46M | 3 | 3 | +36.77% |
| RAPP EDWARD J | director | 2875 0.0002% | $822,250.00 | 5 | 0 | +17.9% |
| WADDELL FREDERICK H | director | 2000 0.0001% | $572,000.00 | 1 | 0 | +22.16% |
$1,927,310,793 | 31 | 28.02% | $1,325.87B | |
$364,368,632 | 29 | 9.65% | $36.8B | |
$6,224,380 | 25 | 3.58% | $640.75B | |
$23,541,811 | 22 | 6.43% | $126.14B | |
AbbVie Inc. (ABBV) | $28,542,809 | 19 | 26.39% | $505.4B |
| Increased Positions | 2,074 | +50.13% | 74M | +5.71% |
| Decreased Positions | 1,834 | -44.33% | 45M | -3.48% |
| New Positions | 403 | New | 9M | New |
| Sold Out Positions | 139 | Sold Out | 8M | Sold Out |
| Total Postitions | 4,377 | +5.8% | 1B | +2.23% |
| Vanguard Group Inc | $40.76M | 10.06% | 177.75M | +448,554 | +0.25% | 2025-09-30 |
| Blackrock, Inc. | $33.47M | 8.26% | 145.98M | -1M | -1% | 2025-09-30 |
| State Street Corp | $18.3M | 4.52% | 79.82M | -202,472 | -0.25% | 2025-09-30 |
| Jpmorgan Chase & Co | $12.96M | 3.2% | 56.53M | -679,591 | -1.19% | 2025-09-30 |
| Morgan Stanley | $9.55M | 2.36% | 41.65M | -45,217 | -0.11% | 2025-09-30 |
| Geode Capital Management, Llc | $9.27M | 2.29% | 40.44M | +1M | +3.22% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $5.95M | 1.47% | 25.96M | -825,223 | -3.08% | 2025-09-30 |
| Capital Research Global Investors | $5.79M | 1.43% | 25.23M | -34,749 | -0.14% | 2025-09-30 |
| Bank Of America Corp /De/ | $5.77M | 1.42% | 25.15M | +45,260 | +0.18% | 2025-09-30 |
| Norges Bank | $5.3M | 1.31% | 23.1M | -2M | -7.94% | 2025-06-30 |